HAMILTON, ON, March 19, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development and commercialization of radiopharmaceuticals, is proud to celebrate its 16th anniversary today. Since 2008, CPDC has been at the forefront of advancing nuclear medicine for patients in Canada and worldwide. On this occasion, the Company extends its sincere appreciation to our many supporters, including the Ontario Institute for Cancer Research and the Government of Canada for their founding and continued financial support.

CPDC proudly acknowledges the recent surge of international attention directed towards its spin-out companies, including Fusion Pharmaceuticals and ARTMS Inc. This significant interest is an affirmation of Canada’s preeminent position in advancing groundbreaking medical isotope technologies.

On this anniversary, CPDC is grateful for the vision of its founding CEO, John Valliant, now CEO of Fusion Pharmaceuticals and a member of the CPDC Board of Directors. CPDC also expresses gratitude for the guidance and support provided by valued Canadian investment partners Genesys Capital and FACIT Inc. Finally, Damian Lamb, Co-Founder and Managing Director of Genesys Capital, deserves special mention for his role as the inaugural Chair of the Board of Fusion Pharmaceuticals, helping to guide our spin-out company’s journey from its inception to its successful initial public offering.

“Our 16th anniversary is an occasion to reflect upon our achievements and to thank all who have supported CPDC over the years, including our past and present Board members, along with industry, academic and government partners, and our partners in the global nuclear medicine community,” said Owen Roberts, CEO of CPDC. “As we look ahead, we remain committed to investing and supporting the development and commercialization of radiopharmaceuticals, and are excited by our pipeline of current projects and opportunities.”